Liver failure as initial presentation of autoimmune hepatitis: Clinical characteristics, predictors of response to steroid therapy, and outcomes
Sumita Verma, Anurag Maheshwari, Paul Thuluvath – 27 March 2009
A woman with chronic anemia and cholestatic liver disease
M. Isabel Fiel, Thomas Schiano – 27 March 2009
Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients
Rami Moucari, Vincent Mackiewicz, Olivier Lada, Marie‐Pierre Ripault, Corinne Castelnau, Michelle Martinot‐Peignoux, Agnes Dauvergne, Tarik Asselah, Nathalie Boyer, Pierre Bedossa, Dominique Valla, Michel Vidaud, Marie‐Hélène Nicolas‐Chanoine, Patrick Marcellin – 27 March 2009 – Pegylated interferon alfa‐2a (PEG‐IFN) may induce sustained virological response (SVR) in 20% of hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B (CHB) patients. In addition, loss of hepatitis B surface antigen (HBsAg) is achieved with a 10% yearly rate after treatment cessation in sustained responders.
A crossing in therapy for hepatitis C virus genotype 2 or 3: Increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration
Chung‐Feng Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu – 27 March 2009
A missense mutation in ABCB4 gene involved in progressive familial intrahepatic cholestasis type 3 leads to a folding defect that can be rescued by low temperature
Jean‐Louis Delaunay, Anne‐Marie Durand‐Schneider, Danièle Delautier, Alegna Rada, Julien Gautherot, Emmanuel Jacquemin, Tounsia Aït‐Slimane, Michèle Maurice – 27 March 2009 – Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare liver disease characterized by early onset of cholestasis that leads to cirrhosis and liver failure before adulthood. PFIC3 may be improved by chronic administration of ursodeoxycholic acid, although in many cases liver transplantation is the only therapy.
Diagnosis, management, and treatment of hepatitis C: An update
Marc G. Ghany, Doris B. Strader, David L. Thomas, Leonard B. Seeff – 27 March 2009
Diagnosis, management, and treatment of hepatitis C: An update
Marc G. Ghany, Doris B. Strader, David L. Thomas, Leonard B. Seeff – 27 March 2009
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats
Marc Mejias, Ester Garcia‐Pras, Carolina Tiani, Rosa Miquel, Jaime Bosch, Mercedes Fernandez – 27 March 2009 – Portal hypertension, the most important complication in patients with cirrhosis of the liver, is a serious and life‐threatening disease for which there are few therapeutic options.
Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma
Shunsuke Ura, Masao Honda, Taro Yamashita, Teruyuki Ueda, Hajime Takatori, Ryuhei Nishino, Hajime Sunakozaka, Yoshio Sakai, Katsuhisa Horimoto, Shuichi Kaneko – 27 March 2009 – MicroRNA (miRNA) plays an important role in the pathology of various diseases, including infection and cancer.
The perils and promise of high‐dimensional biology
Terry Therneau – 27 March 2009